BRIDGETTE REID: Open Payments
NPI 1962035634 · KISSIMMEE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,695 in 106 payments from 14 companies in 2025. Trend: 2023 $1,054 · 2024 $1,207 · 2025 $2,695
Food & beverage: $2,695
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $767 |
| Teva Pharmaceuticals USA, Inc. | 19 | $528 |
| Neurocrine BioSciences, Inc. | 12 | $449 |
| Otsuka America Pharmaceutical, Inc. | 15 | $283 |
| Janssen Pharmaceuticals, Inc | 10 | $150 |
| Noven Therapeutics, LLC | 1 | $122 |
| ACADIA Pharmaceuticals Inc | 4 | $113 |
| E.R. Squibb & Sons, L.L.C. | 5 | $102 |
| Vanda Pharmaceuticals Inc. | 4 | $70 |
| Luye Pharma (USA) Ltd. | 2 | $36 |
Products named: VRAYLAR, AUSTEDO XR, INGREZZA, REXULTI, INVEGA SUSTENNA, Xelstrym, NUPLAZID, COBENFY.
Industry payments across FL — which companies pay providers there.
